We agree with André et al. (Nature 626, 26–29; 2024) that personalized cancer treatment is crucial, and that molecular testing has a part to play. But disease specificity remains an important determinant of high-quality cancer care.
Competing Interests
Table of Contents
The authors declare no competing interests.